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longer-acting opiate. Short-acting opiates, however, have
the potential to reduce time to extubation (TTE) and
may, therefore, decrease length of stay (LOS) and hospi-
tal costs. Remifentanil was added to our institution’s
formulary for use during off-pump bypass surgery. The
objective of this analysis was to compare TTE, LOS
and total hospital costs between patients who received
remifentanil and fentanyl during off-pump bypass sur-
gery. METHODS: The study was prospective and obser-
vational in design. Consecutive patients who underwent
off-pump cardiac bypass surgery and received either
remifentanil or fentanyl from September 1998 to August
1999 were included. Patient charges were converted to
costs using cost-to-charge ratios. The percent of patients
extubated in the operating room (OR), LOS and hospital
costs were compared between the groups. RESULTS:
Baseline demographics, including age, female patients,
co-morbidities and intraoperative variables were similar
between the remifentanil (n  39) and fentanyl (n  20)
groups. Patients given remifentanil during surgery were
significantly more likely to be extubated in the OR than
patients given fentanyl (64% vs. 15%; p  0.001). The
mean LOS was similar in both groups (7.3  3.1d vs. 8.3 
2.7d; p  0.27). Patients who received remifentanil in-
curred lower ward ($3,973  1,719 vs. $4,808  1,794;
p  0.09), recovery room ($31  40 vs. $65  33; p 
0.002) and pulmonary function testing costs ($0  0 vs.
$34  103; p  0.045) than patients who received fenta-
nyl. Anesthesia costs were higher among patients who re-
ceived remifentanil ($476  102 vs. $416  130; p 
0.06). Medical and surgical supplies, OR, ICU, cardiac
catheterization, laboratory, respiratory therapy, phar-
macy, radiology and transfusion costs were similar be-
tween the 2 groups (p  0.05). The total cost was
$15,272  5,556 and $15,616  4,169 in the remifenta-
nil and fentanyl groups, respectively (p  0.81). CON-
CLUSION: Remifentanil, when used in off-pump bypass
surgery, increases the likelihood of extubation in the OR.
However, LOS and total hospital costs remain un-
changed.
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BACKGROUND: Atrial Fibrillation (AF) is the most fre-
quent type of arrhythmia. Termination of acute AF is
generally undertaken in a hospital setting. Available
drugs for termination of acute AF have severe side effects
and complicated dose regimens. There is a need for new
drugs with a high conversion rate, favourable safety pro-
file and easier dosing. OBJECTIVES: To describe the
characteristics and hospital treatment patterns of patients
with AF. To investigate the requirements for an improved
cost-effective anti-arrhythmic therapy. METHODS: A
database was used containing aggregated and anonymised
diagnostic information, hospital experience (e.g., length
of stay), and demographic data for over 80 million inpa-
tient episodes in the UK over ten years. The database
contains 28,524 hospital admissions of patients (65 and
over) with a diagnosis of AF during 1999/2000. 53.3%
are female, with mean length of stay (LOS) 6.1 days;
46.7% are male with LOS 4.3 days. Controlling for age,
the gender LOS difference is significant (p  0.01). RE-
SULTS: Comorbid Conditions. 17.5% of AF patients
also had a diagnosis of chronic ischaemic heart disease
(IHD), a further 7.5% had myocardial ischaemia, and
19.5%, congestive heart failure. Furthermore, 24.2% of
CHF patients and 16.9% of all angina patients also had
clinically significant AF. Cardioversion. Cardioversion
(defibrillation) is used when pharmacological therapy
fails to terminate acute AF. However, significant num-
bers (35%) of cardioversion procedures were undertaken
on an elective day case basis. We are currently investigat-
ing and will report on the resource consequences in acute
AF. CONCLUSIONS: There is a clear unmet medical
need for improved anti-arrhythmic drugs. Using the
dataset, we identify two potentially cost-effective possi-
bilities for improved anti-arrhythmic treatment: an agent
which can simultaneously demonstrate effectiveness in
associated cardiovascular conditions such as IHD or
CHF; or an agent reducing the need for cardioversion in
acute AF.
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Prophylactic infusion of factor VIII has been shown to
markedly reduce arthropathy in patients with severe he-
mophilia A. OBJECTIVE: The purpose of this model is
to investigate the cost-effectiveness of prophylactic infu-
sion of factor VIII relative to on-demand infusion therapy
in patients with severe hemophilia A. METHODS: Two
hypothetical cohorts were modeled; one cohort receiving
prophylactic and the other on-demand infusions. Factor
VIII infusion therapy begins at age 1 and continues un-
changed over a patient’s lifetime. A recursive Markov
model is used to estimate the expected costs and QALYs
associated with each cohort. Costs and QALYs are calcu-
lated using backward induction in 5-year intervals incor-
porating the DEALE method. Data inputs are estimated
from published literature. The analysis is completed from
a societal perspective, uses a 3% discount rate, with costs
in year 2000 U.S. dollars, and has a time horizon of 50
years. RESULTS: According to the model, patients re-
